Delivery Order SPE2DB25D3006-SPE2DB25FXKAS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,836.26 to AmerisourceBergen Drug Corp for the supply of Tafinlar 50 mg capsules (120 count) on September 4, 2025, with an ultimate completion date of September 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tafinlar (dabrafenib) is a targeted cancer therapy used primarily for melanoma...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tafinlar 75 mg capsules (120 count) with a ceiling value of $8,896.41. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order is scheduled for completion by September 12, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- This is a $8,896.41 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for Tafinlar 75 mg capsules, a medication used to treat certain types of cancer. The contract has an ultimate completion date of June 26, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tafinlar 75 mg capsules (120-count units) under a firm fixed-price contract. The award, valued at $17,792.82, is set to be completed by September 12, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform fulfillment from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $8,896.41 delivery order to AmerisourceBergen Drug Corp for Tafinlar 75 mg capsules (120 count) on July 17, 2025, with an ultimate completion date of August 7, 2025. This firm fixed price delivery order, issued without set-aside designation, was competitively awarded and performed at the contractor's Conshohocken, Pennsylvania location. The award represents a single shipment of this oncology medication through AmerisourceBergen's established federal...
- The Defense Logistics Agency awarded a delivery order valued at $8,896.41 to AmerisourceBergen Drug Corp for the supply of Tafinlar 75 mg capsules (120-count units), with an ultimate completion date of May 30, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tafinlar 50 mg capsules (120-count units) with a ceiling value of $13,836.26. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a competitively awarded, non-set-aside contract with no small business preferences applied. The work is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- This is a $35,585.64 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Tafinlar 75 mg capsules, a medication used in the treatment of certain types of cancer. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 120 capsules of Tafinlar 75 mg, a chemotherapy medication used primarily for melanoma treatment. This firm fixed-price delivery order, valued at $8,896.41, was awarded on July 21, 2025, with an ultimate completion date of August 11, 2025. The contract was not set aside and represents a competitively awarded transaction under the company's existing contract vehicle. Performance will occur at...
- The Defense Logistics Agency awarded a delivery order valued at $8,896.41 to AmerisourceBergen Drug Corp for the supply of Tafinlar 75 mg capsules (120 count) on August 29, 2025, with an ultimate completion date of September 22, 2025. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in...
- SPE2DB25D3006Indefinite Delivery Contract
- SPE2DB25D3006-SPE2DB25FXKASDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,896.41 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tafinlar 75 mg capsules (120-count). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 2, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tafinlar (dabrafenib) is a targeted cancer therapy used in the treatment of melanoma and other malignancies, reflecting the critical pharmaceutical support that AmerisourceBergen provides to the federal healthcare system. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The company's extensive portfolio of federal contract awards demonstrates its role as a critical vendor for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with all reviewed awards competitively awarded under non-set-aside conditions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 8/11/25 |